|
0
|
|
Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy.
(academic.oup.com)
|
Peng Q
…
Jin X
Journal of Infectious Diseases
2026-07-14
|
#vaccination
#immunogenicity
#hiv
#clinical trial
#immunotherapy
|
|
0
|
|
A favorable follicular helper CD4 T cell programming characterizes neutralization activity in chronic HIV infection.
(jci.org)
|
Moysi E
…
Petrovas C
Journal of Clinical Investigation
2026-07-14
|
#hiv
#immunity
#antibody
#immunology
|
|
0
|
|
Rapid Achievement of Protective Cabotegravir Concentrations in a real-world HIV PrEP cohort.
(linkinghub.elsevier.com)
|
Moschese D
…
Cossu MV
International Journal of Antimicrobial Agents
2026-07-14
|
#pharmacokinetics
#hiv
#prep
#therapeuticdrugmonitoring
|
|
0
|
|
Structural basis of membrane engagement and polyreactivity control in HIV-1 MPER broadly neutralizing antibodies.
(pnas.org)
|
Cho SY
…
Wilson IA
PNAS
2026-07-14
|
#antibody
#hiv
#neutralization
#crystallography
#epitope
|
|
0
|
|
Biosocial influences of gender identity and geography on mucosal microbial phenotypes.
(nature.com)
|
Van Doren VE
…
Kelley CF
Communications Medicine
2026-07-14
|
#microbiome
#metagenomics
#hormones
#hiv
|